'The tubercular diabetic': The impact of diabetes mellitus on tuberculosis and its threat to global tuberculosis control

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 11, Issue 4, 2011, Pages 344-347

  Bailey, Sarah Lou ^a   Grant, Paul ^b  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

AIDS; Diabetes mellitus; DOTS; Global health; HIV; Tuberculosis

Indexed keywords

ORAL ANTIDIABETIC AGENT; RIFAMPICIN;

ARTICLE; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; MORBIDITY; SHORT COURSE THERAPY; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 80051769252     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.11-4-344     Document Type: Article

References (26)

1. Root H. The association of diabetes and tuberculosis. New Engl J Med 1934;210:1-13.
2. World Health Organization. Global tuberculosis control: a short update to the 2009 report. Geneva: WHO, 2009.
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53. (Pubitemid 38579764)
4. Banerjee S, Banerjee M. Diabetes and tuberculosis interface. J Indian Med Assoc 2005;103:318,320,322 passim.
5. Bashar M, Alcabes P, Rom WN, Condos R. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest 2001;120:1514-9. (Pubitemid 33078466)
6. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008;5:e152.
7. Stevenson CR, Forouhi NG, Roglic G et al. Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health 2007;7:234.
8. Mugusi F, Swai AB, Alberti KG, McLarty DG. Increased prevalence of diabetes mellitus in patients with pulmonary tuberculosis in Tanzania. Tubercle 1990;71:271-6.
9. Restrepo BI, Fisher-Hoch SP, Crespo JG et al. Type 2 diabetes and tuberculosis in a dynamic bi-national border population. Epidemiol Infect 2007;135:483-91. (Pubitemid 46443434)
10. Lindoso AA, Waldman EA, Komatsu NK et al. Profile of tuberculosis patients progressing to death, city of Sao Paulo, Brazil, 2002. Rev Saude Publica 2008;42:805-12.
11. Pablos-Mendez A, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health 1997;87:574-9. (Pubitemid 27208742)
12. Wang CS, Yang CJ, Chen HC et al. Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol Infect 2009;137:203-10.
13. Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg 2009;80:634-9.
14. Singla R, Khan N, Al-Sharif N et al. Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients. Int J Tuberc Lung Dis 2006;10:74-9. (Pubitemid 43266281)
15. Banu Rekha VV, Balasubramanian R, Swaminathan S et al. Sputum conversion at the end of intensive phase of category-1 regimen in the treatment of pulmonary tuberculosis patients with diabetes mellitus or HIV infection: an analysis of risk factors. Indian J Med Res 2007;126:452-8. (Pubitemid 351663602)
16. Nissapatorn V, Kuppusamy I, Jamaiah I et al. Tuberculosis in diabetic patients: a clinical perspective. Southeast Asian J Trop Med Public Health 2005;36(Suppl 4):213-20.
17. Fisher-Hoch SP, Whitney E, McCormick JB et al. Type 2 diabetes and multidrug-resistant tuberculosis. Scand J Infect Dis 2008;40:888-93.
18. Subhash HS, Ashwin I, Mukundan U et al. Drug resistant tuberculosis in diabetes mellitus: a retrospective study from south India. Trop Doct 2003;33:154-6. (Pubitemid 36791961)
19. Suarez-Garcia I, Rodriguez-Blanco A, Vidal-Perez JL et al. Risk factors for multidrug-resistant tuberculosis in a tuberculosis unit in Madrid, Spain. Eur J Clin Microbiol Infect Dis 2009;28:325-30.
20. Stalenhoef JE, Alisjahbana B, Nelwan EJ et al. The role of interferon-gamma in the increased tuberculosis risk in type 2 diabetes mellitus. Eur J Clin Microbiol Infect Dis 2008;27:97-103. (Pubitemid 351171510)
21. Takasu N, Yamada T, Miura H et al. Rifampicin-induced early phase hyperglycemia in humans. Am Rev Respir Dis 1982;125:23-7. (Pubitemid 12216102)
22. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003;42:819-50. (Pubitemid 36995083)
23. Nijland HM, Ruslami R, Stalenhoef JE et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 2006;43:848-54. (Pubitemid 44435511)
24. Harries AD, Jahn A, Zachariah R, Enarson D. Adapting the DOTS framework for tuberculosis control to the management of noncommunicable diseases in sub-Saharan Africa. PLoS Med 2008;5:e124.
25. The International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-34.
26. Hawkins RC. Comparison of four point-of-care HbA1c analytical systems against central laboratory analysis. Singapore Med J 2003;44:8-11. (Pubitemid 36432977)